The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1

Chi,Liyi; Peng,Lijing; Pan,Na; Hu,Xiaojing; Zhang,Yanhai

doi:10.3892/ijmm.2014.1868

The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1

Authors:
- Liyi Chi
- Lijing Peng
- Na Pan
- Xiaojing Hu
- Yanhai Zhang
View Affiliations

Affiliations: Department of Neurology, The 451st Hospital of People's Liberation Army, Xi'an, Shaanxi 710054, P.R. China , Department of Cardiovascular Medicine, The 451st Hospital of People's Liberation Army, Xi'an, Shaanxi 710054, P.R. China , Department of Cardiovascular Medicine, Ninth Hospital of Xi'an, Xi'an, Shaanxi 710054, P.R. China, Department of Cadres Ward, The 451st Hospital of People's Liberation Army, Xi'an, Shaanxi 710054, P.R. China
Published online on: July 28, 2014 https://doi.org/10.3892/ijmm.2014.1868
Pages: 1087-1093

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Berberine (BBR) is a botanical alkaloid that has been reported to have effects in cardiovascular diseases; however, the mechanisms involved are not yet fully understood. In the present study, the protective effects of BBR were evaluated, and the underlying molecular mechanisms were investigated. The effects of a combination of atorvastatin and BBR on foam cell formation were also investigated. THP-1-derived macrophages were pre-treated with BBR (5, 10 and 20 mg/l) for 2 h prior to the addition of oxidized low density lipoprotein (ox-LDL; 50 mg/l). Small interfering RNA (siRNA) targeting sirtuin 1 (SIRT1) and the adenosine 5'-monophosphate-activated protein kinase (AMPK) inhibitor, compound C, were used to investigate the mechanisms through which BBR exerts its effects. To determine the effect of a combination of atorvastatin and BBR, the macrophages were treated with atorvastatin and BBR separately or jointly for 2 h, and then treated with ox-LDL (50 mg/l) or lipopolysaccharide (LPS; 10 µM) for 12 h. Oil Red O staining was used to detect foam cell formation. Lipid amounts were assessed by high-performance liquid chromatography (HPLC). Gene and protein expression was evaluated by RT-qPCR, western blot analysis and enzyme-linked immunosorbent assay (ELISA) carried out separately or jointly. The results from Oil Red O staining and HPLC revealed that BBR effectively suppressed foam cell formation and lipid and cholesterol accumulation. Furthermore, BBR upregulated the expression of SIRT1 and AMPK and downregulated the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ). Pre-treatment of the cells with SIRT1-siRNA or compound C attenuated the anti-atherosclerotic effects of BBR. The results obtained in the present study demonstrate that the combination of atorvastatin and BBR is more effective in inhibiting foam cell formation than using atorvastatin alone. These data suggest that BBR suppresses foam cell formation by activating the AMPK-SIRT1-PPAR-γ pathway and diminishing the uptake of ox-LDL. Combination therapy with BBR and atorvastatin was more effective in preventing atherosclerotic processes than atorvastatin alone.

View Figures

View References

1	Zhao JF, Jim Leu SJ, Shyue SK, Su KH, Wei J and Lee TS: Novel effect of paeonol on the formation of foam cells: promotion of LXRα-ABCA1-dependent cholesterol efflux in macrophages. Am J Chin Med. 41:1079–1096. 2013.PubMed/NCBI
2	Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 352:1685–1695. 2005. View Article : Google Scholar
3	Weber C, Zernecke A and Libby P: The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 8:802–815. 2008. View Article : Google Scholar : PubMed/NCBI
4	Boring L, Gosling J, Cleary M and Charo IF: Decreased lesion formation in CCR2^−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:894–897. 1998. View Article : Google Scholar : PubMed/NCBI
5	Edfeldt K, Swedenborg J, Hansson GK and Yan ZQ: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 105:1158–1161. 2002.PubMed/NCBI
6	Li AC and Glass CK: The macrophage foam cell as a target for therapeutic intervention. Nat Med. 8:1235–1242. 2002. View Article : Google Scholar : PubMed/NCBI
7	Voloshyna I, Hai O, Littlefield MJ, Carsons S and Reiss AB: Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARγ and adenosine. Eur J Pharmacol. 698:299–309. 2013.PubMed/NCBI
8	Stein S, Lohmann C, Schafer N, et al: SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J. 31:2301–2309. 2010. View Article : Google Scholar : PubMed/NCBI
9	Picard F, Kurtev M, Chung N, et al: Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature. 429:771–776. 2004.PubMed/NCBI
10	Vaziri H, Dessain SK, Ng Eaton E, et al: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 107:149–159. 2001.PubMed/NCBI
11	Zhang QJ, Wang Z, Chen HZ, et al: Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res. 80:191–199. 2008. View Article : Google Scholar : PubMed/NCBI
12	Huang Z, Dong F, Li S, et al: Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages. Eur J Pharmacol. 690:164–169. 2012. View Article : Google Scholar
13	Kong W, Wei J, Abidi P, et al: Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 10:1344–1351. 2004. View Article : Google Scholar : PubMed/NCBI
14	Yin J, Xing H and Ye J: Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 57:712–717. 2008. View Article : Google Scholar : PubMed/NCBI
15	Liu X, Li G, Zhu H, et al: Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. Endocr J. 57:881–893. 2010.PubMed/NCBI
16	Zhu X, Guo X, Mao G, et al: Hepatoprotection of berberine against hydrogen peroxide-induced apoptosis by upregulation of Sirtuin 1. Phytother Res. 27:417–421. 2013. View Article : Google Scholar : PubMed/NCBI
17	Guan S and Wang B: Effects of fosinopril and valsartan on expressions of ICAM-1 and NO in human umbilical vein endothelial cells. Chin Med J (Engl). 116:923–927. 2003.PubMed/NCBI
18	Winnik S, Stein S and Matter CM: SIRT1 - an anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis. Curr Vasc Pharmacol. 10:693–696. 2012. View Article : Google Scholar : PubMed/NCBI
19	Vingtdeux V, Chandakkar P, Zhao H, Davies P and Marambaud P: Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med. 17:1022–1030. 2011. View Article : Google Scholar : PubMed/NCBI
20	Fullerton MD, Steinberg GR and Schertzer JD: Immunometabolism of AMPK in insulin resistance and atherosclerosis. Mol Cell Endocrinol. 366:224–234. 2013. View Article : Google Scholar : PubMed/NCBI
21	Canto C, Jiang LQ, Deshmukh AS, et al: Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. 11:213–219. 2010. View Article : Google Scholar : PubMed/NCBI
22	Hardie DG: AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 8:774–785. 2007. View Article : Google Scholar : PubMed/NCBI
23	Charo IF and Taubman MB: Chemokines in the pathogenesis of vascular disease. Circ Res. 95:858–866. 2004. View Article : Google Scholar : PubMed/NCBI
24	McLaren JE, Michael DR, Ashlin TG and Ramji DP: Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res. 50:331–347. 2011. View Article : Google Scholar : PubMed/NCBI
25	Chen FL, Yang ZH, Liu Y, et al: Berberine inhibits the expression of TNFα, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARγ pathway. Endocrine. 33:331–337. 2008.
26	Zhu GY, Zhu XL, Li RT, Liu TB, Shang DY and Zhang Y: Atorvastatin inhibits scavenger receptor A and monocyte chemoattractant protein-1 expressions in foam cell. Zhonghua Xin Xue Guan Bing Za Zhi. 35:666–669. 2007.(In Chinese).
27	Kawai H, Kurata T, Deguchi K, et al: Combination benefit of amlodipine plus atorvastatin treatment on carotid atherosclerosis in Zucker metabolic rats. Neurol Res. 35:181–186. 2013. View Article : Google Scholar : PubMed/NCBI
28	Guan S, Wang B, Li W, Guan J and Fang X: Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. Am J Chin Med. 38:1161–1169. 2010. View Article : Google Scholar : PubMed/NCBI
29	Kunjathoor VV, Febbraio M, Podrez EA, et al: Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 277:49982–49988. 2002. View Article : Google Scholar : PubMed/NCBI
30	Rader DJ and Pure E: Lipoproteins, macrophage function, and atherosclerosis: beyond the foam cell? Cell Metab. 1:223–230. 2005. View Article : Google Scholar : PubMed/NCBI
31	Abidi P, Zhou Y, Jiang JD and Liu J: Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol. 25:2170–2176. 2005. View Article : Google Scholar
32	Brusq JM, Ancellin N, Grondin P, et al: Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res. 47:1281–1288. 2006. View Article : Google Scholar : PubMed/NCBI
33	Li L, Sawamura T and Renier G: Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res. 94:892–901. 2004. View Article : Google Scholar : PubMed/NCBI
34	Liang KW, Ting CT, Yin SC, et al: Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem Pharmacol. 71:806–817. 2006. View Article : Google Scholar : PubMed/NCBI
35	Yokozawa T, Ishida A, Kashiwada Y, Cho EJ, Kim HY and Ikeshiro Y: Coptidis Rhizoma: protective effects against peroxynitrite-induced oxidative damage and elucidation of its active components. J Pharm Pharmacol. 56:547–556. 2004. View Article : Google Scholar
36	Cho BJ, Im EK, Kwon JH, et al: Berberine inhibits the production of lysophosphatidylcholine-induced reactive oxygen species and the ERK1/2 pathway in vascular smooth muscle cells. Mol Cells. 20:429–434. 2005.PubMed/NCBI
37	Wang ZH, Liu XL, Zhong M, et al: Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. J Clin Pharmacol. 50:311–319. 2010. View Article : Google Scholar : PubMed/NCBI